Kristopher R. Bosse

This study identifies MIF as a key immunosuppressive factor in neuroblastoma that inhibits CAR T-cell efficacy, showing that blocking MIF enhances T-cell activation and therapeutic potential.

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.

This study identifies BARD1 germline variants associated with reduced BARD1 expression and DNA repair defects in neuroblastoma, showing haploinsufficiency and increased genomic instability.

This study identifies 13.9% of neuroblastoma patients with pathogenic germline variants in cancer predisposition genes, associated with worse survival and enriched in DNA repair genes like BARD1.